Fig 1: Expression of markers of neuronal differentiation. The entire panel of GSC lines was stained for SV2A, NeuN, vGlut1, GAD67 and synaptophysin. Representative staining of each marker from the GSC line R28 are shown. Single cells are shown with higher magnification in the inset given in the left upper corner. DAPI counterstaining was used to visualize nuclei.
Fig 2: Association of vGlut1 expression with clinical characteristics. (A,B) Risk of seizures at onset (A) and at any time point during disease (B) in patients with high, intermediate, low and no vGlut1 expression. (C) Survival of patients with high, intermediate, low and no vGlut1 expression (p = 7., Log-Rank test). (D) MGMT methylation status in patients with high, intermediate, low and no vGlut1 expression. (E) Proportion of cells with spontaneous changing intracellular calcium concentrations within 5 min periods.
Fig 3: Glutamatergic and GABAergic glioma cells. (A,B) Westernblot of GSC lines and control samples (breast cancer cell line MCF7, classical glioma cell lines T98G, U87). Blots were probed with antibodies against GAD67, synaptophysin, SV2A and vGlut1. Actin was used as loading control. (C) Immunocytochemistry against vGlut1 and synaptophysin. DAPI was used to label the nuclei. (D,E) Correlation of synaptophysin expression with vGlut1 (Pearson r = 0.92, p < 0.001) and GAD67 (Pearson r = 0.36, p = 0.001) using mRNA expression data from the RemBranDT database (accessed: 09 January 2018).
Supplier Page from Abcam for Anti-VGluT1 antibody [N28-9] (Alexa Fluor® 488)